Calendar

Abstract:

D-10 Therapeutics, Inc. is an early-stage biotech company focused on developing a novel therapy for sickle cell disease (SCD), an orphan indication with few available and often life-threatening treatments. Our compound's development aligns with the primary treatment objectives established by the global medical community, as highlighted by the American Society of Hematology.

D-10 Therapeutics, Inc. aims to create a monoclonal antibody treatment that prevents damage to blood vessels by stopping sickle cells from binding to the vessel walls. This is achieved by blocking the receptors that allow sickle cells to adhere. Additionally, our monoclonal antibody treatment will induce the relaxation of smooth muscle cells within the blood vessels, thereby widening the passage for blood cells to flow freely.

D-10 Therapeutics, Inc. intends to formulate this compound for intravenous infusion and/or subcutaneous injection, enhancing patient compliance and making the treatment accessible to medically underserved ethnic groups in the USA and globally, who are most affected by SCD. By providing a disease-modifying treatment, D-10 Therapeutics, Inc. aims to change the course of sickle cell disease by targeting the underlying mechanisms of the condition rather than merely alleviating pain temporarily.

PRESENTER INFORMATION